Invivogen
Menu

InvivoGen's product citations

Citations

InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).

Citations search

You can search by ‘Product Name’ or ‘Year’.

Find a citation by product name
Enter a year of publication
Product Citation Year Journal Authors Page
NLRP3 KO & KD THP-1 Cells Pathogen and human NDPK-proteins promote AML cell survival via monocyte NLRP3... 2023 PLoS One Trova S. et al. DOI: 10.1371/journal.pone.0288162
THP1-defCASP1 Cells Pathogen and human NDPK-proteins promote AML cell survival via monocyte NLRP3... 2023 PLoS One Trova S. et al. DOI: 10.1371/journal.pone.0288162
Primocin® Effect of aging on the formation and growth of colonic epithelial organoids b... 2023 Inflamm Regen. Jo M.K. et al. DOI: 10.1186/s41232-023-00282-6
Imiquimod VacciGrade™ (R837) Secretory leukocyte protease inhibitor modulates FcεRI-dependent but not Mrgp... 2023 Int Immunopharmacol Kwiecinska P. et al. DOI: 10.1016/j.intimp.2023.110631
Puromycin High-throughput functional screen identifies YWHAZ as a key regulator of panc... 2023 Cell Death Dis. Cao F. et al. DOI: 10.1038/s41419-023-05951-5
2'3'-cGAMP Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of la... 2023 Sci Adv. Cheng F. et al. DOI: 10.1126/sciadv.ade6257
RAW-Lucia™ ISG Cells Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of la... 2023 Sci Adv. Cheng F. et al. DOI: 10.1126/sciadv.ade6257
QUANTI-Luc™: Luciferase Detection Reagent Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of la... 2023 Sci Adv. Cheng F. et al. DOI: 10.1126/sciadv.ade6257
Plasmocin® - Mycoplasma Elimination Reagent In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. 2023 Nat Commun. Kiso M. et al. DOI: 10.1038/s41467-023-40018-1
G418 (Geneticin) In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. 2023 Nat Commun. Kiso M. et al. DOI: 10.1038/s41467-023-40018-1
RAW-Lucia™ ISG Cells Investigation of the enhanced antitumour potency of STING agonist after conju... 2023 Nat Nanotechnol. Dosta P. et al. DOI: 10.1038/s41565-023-01447-7
QUANTI-Luc™: Luciferase Detection Reagent Investigation of the enhanced antitumour potency of STING agonist after conju... 2023 Nat Nanotechnol. Dosta P. et al. DOI: 10.1038/s41565-023-01447-7
RAW-Lucia™ ISG-KO-STING Cells Investigation of the enhanced antitumour potency of STING agonist after conju... 2023 Nat Nanotechnol. Dosta P. et al. DOI: 10.1038/s41565-023-01447-7
THP1-Dual™ Cells Investigation of the enhanced antitumour potency of STING agonist after conju... 2023 Nat Nanotechnol. Dosta P. et al. DOI: 10.1038/s41565-023-01447-7
QUANTI-Blue™ Investigation of the enhanced antitumour potency of STING agonist after conju... 2023 Nat Nanotechnol. Dosta P. et al. DOI: 10.1038/s41565-023-01447-7
Poly(I:C) HMW RelB-deficient autoinflammatory pathology presents as interferonopathy, but i... 2023 J Allergy Clin Immunol. Navarro H.I. et al. DOI: 10.1016/j.jaci.2023.06.024
ODN 1668 - TLR9 ligand RelB-deficient autoinflammatory pathology presents as interferonopathy, but i... 2023 J Allergy Clin Immunol. Navarro H.I. et al. DOI: 10.1016/j.jaci.2023.06.024
ODN 2395 - TLR9 ligand A protocol for high-throughput screening for immunomodulatory compounds using... 2023 STAR Protoc. Chew K. et al. DOI: 10.1016/j.xpro.2023.102405
R848 (Resiquimod) A protocol for high-throughput screening for immunomodulatory compounds using... 2023 STAR Protoc. Chew K. et al. DOI: 10.1016/j.xpro.2023.102405
TLR4-based adjuvant - MPLA-SM VacciGrade™ CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immu... 2023 PLoS One Laotee S. et al. DOI: 10.1371/journal.pone.0288486

Pages

Customer Service
& Technical Support
Contact us
Shopping cart is empty